Results 41 to 50 of about 3,628 (221)

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. [PDF]

, 2020
BackgroundSome trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial ...
Ballantyne, Christie M, Bhatt, Deepak L, Brinton, Eliot A, Budoff, Matthew J, Chung, Mina K, Doyle, Ralph T, Gibson, C Michael, Giugliano, Robert P, Granowitz, Craig, Jacobson, Terry A, Jiao, Lixia, Juliano, Rebecca A, Ketchum, Steven B, Miller, Michael, Olshansky, Brian, REDUCE-IT Investigators, Steg, Ph Gabriel, Tardif, Jean-Claude   +17 more
core   +1 more source

GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets. [PDF]

, 2020
G protein-coupled receptors (GPCRs) mediate the majority of platelet activation in response to agonists. However, questions remain regarding the mechanisms that provide negative feedback toward activated GPCRs to limit platelet activation and thrombus ...
Benovic, Jeffrey, Brass, Lawrence F., Chen, Xi, Cooper, Matthew, DeHelian, Daniel, Goldfinger, Lawrence E., Gupta, Shuchi, Ma, Peisong, McKenzie, Steven E., Naik, Meghna U., Naik, Ulhas P., Stalker, Timothy J., Wurtzel, Jeremy G.T., Zhao, Xuefei   +13 more
core   +1 more source

Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. [PDF]

, 2014
In this study the role of P2Y12 receptors (P2Y12R) was explored in rodent models of inflammatory and neuropathic pain and in acute thermal nociception.
Andó, Rómeó, Baranyi, Mária, Csölle, Cecília, Gölöncsér, Flóra, Horváth, Gergely, Király, Kornél P., Máté, Zoltán, Sperlágh, Beáta   +7 more
core   +1 more source

P2Y12 platelet inhibition in clinical practice [PDF]

, 2011
Platelet adhesion, activation and aggregation play a pivotal role in atherothrombosis. Intracoronary atherothrombosis is the most common cause of the development of acute coronary syndrome (ACS), and plays a central role in complications occurring around
Peter Damman, Pier Woudstra, Wichert J. Kuijt, Robbert J. de Winter, Stefan K. James   +4 more
core   +1 more source

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y12 Inhibitors is Not Feasible or Desirable, in Spain

ClinicoEconomics and Outcomes Research, 2021
Irene Lizano-Díez,1 Silvia Paz Ruiz2 1Ferrer, Barcelona, Spain; 2SmartWorking4U SLU, Benicàssim, SpainCorrespondence: Irene Lizano-DíezFerrer, Av Diagonal 549, Barcelona 08029, SpainTel +34 93 600 37 00Email ilizano@ferrer.comPurpose:
Lizano-Díez I, Paz Ruiz S
doaj  

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study

International Journal of Cardiology: Heart & Vasculature
Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. Methods: The PharmacOdynaMic effects
Giuseppe Gargiulo, Plinio Cirillo, Luca Sperandeo, Imma Forzano, Domenico Simone Castiello, Domenico Florimonte, Fiorenzo Simonetti, Roberta Paolillo, Lina Manzi, Alessandra Spinelli, Carmen Anna Maria Spaccarotella, Raffaele Piccolo, Luigi Di Serafino, Anna Franzone, Piera Capranzano, Marco Valgimigli, Giovanni Esposito   +16 more
doaj   +1 more source

The Arranged Marriage of Cangrelor and Bivalirudin

JACC: Cardiovascular Interventions, 2015
Bivalirudin and cangrelor are 2 intravenous drugs, 1 for anticoagulation and the other for antiplatelet therapy, with a rapid onset of action, thus in theory perfectly adapted to percutaneous coronary intervention (PCI) that requires simultaneous thrombin and platelet inhibition.
Montalescot, Gilles, Helft, Gérard
openaire   +2 more sources